newsfilter
← Latest News
Business Wire·

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Once issued, this new U.S. Patent will expand the scope of Enveric's EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions. Enveric Biosciences (NASDAQ:ENVB)